Article
No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population.
Psychiatric genetics - 1 Feb 2020
Zhang Naixing, Ji Lei, Chen Zhixuan, An Lin, Ren Decheng, Bi Yan, Guo Zhenming, Yuan Ruixue, Yuan Fan, Dong Zaiquan, Yin Li, Sun Xueli, Yang Fengping, Li Xingwang, Yu Tao, He Lin, Shi Lei, He Guang
Abstract excerpt
OBJECTIVE: Major depressive disorder (MDD) is a global mental health problem. As a serotonin-noradrenaline reuptake inhibitor (SNRI), the antidepressant venlafaxine is used to alleviate MDD clinically. Recent research has shown that Cytochrome P450 (CYP) enzymes affect venlafaxine efficacy by mediating its metabolism. The present study investigates genetic polymorphisms of cytochrome P450 family 2 subfamily C...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
